中国医学科学院血液病医院(血液学研究所)
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
中国医学科学院血液病医院(血液学研究所)的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma47 篇牵头论文牵头 28 项开放试验
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia13 篇牵头论文牵头 12 项开放试验
- 再生障碍性贫血Aplastic anaemia48 篇牵头论文牵头 9 项开放试验
- β 地中海贫血Beta thalassaemia1 篇牵头论文
- 血友病 AHaemophilia A25 篇牵头论文牵头 5 项开放试验
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
- 范可尼贫血Fanconi anaemia3 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
- 戈谢病Gaucher disease0 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、尤文肉瘤、噬血细胞性淋巴组织细胞增生症、非典型溶血性尿毒症综合征、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、IgA 肾病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
天津有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 47 篇,占 2.8%。
天津有 5 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 52
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2026-01
- 登记号
- NCT07322159
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- 分期
- II期
- 开始
- 2026-07
- 登记号
- NCT07409454
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- 分期
- II期
- 开始
- 2026-09
- 登记号
- NCT07585760
年龄 18 岁 至 80 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- 分期
- II期
- 开始
- 2026-09
- 登记号
- NCT07652905
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT06793449
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- 分期
- 不分期
- 开始
- 2025-04
- 登记号
- NCT06793475
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募BCMA CAR-T for Dynamic High-risk Multiple Myeloma
- 分期
- II期
- 开始
- 2025-03
- 登记号
- NCT06880393
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募A Study of CT0596 in Plasma Cell Leukemia
- 分期
- 早期I期
- 开始
- 2025-06
- 登记号
- NCT06988059
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- 分期
- II期
- 开始
- 2025-08
- 登记号
- NCT07106671
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
- 分期
- II期
- 开始
- 2025-08
- 登记号
- NCT07106684
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
- 分期
- II期
- 开始
- 2025-08
- 登记号
- NCT07106710
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- 分期
- II期
- 开始
- 2025-08
- 登记号
- NCT07106736
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
- 分期
- I/II期
- 开始
- 2025-03
- 登记号
- NCT07109323
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
- 分期
- I/II期
- 开始
- 2025-03
- 登记号
- NCT07169500
年龄 18 岁 至 50 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2025-03
- 登记号
- NCT07249073
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06745687
年龄 18 岁 至 78 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- 分期
- II期
- 开始
- 2023-08
- 登记号
- NCT05979363
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- 分期
- II期
- 开始
- 2023-12
- 登记号
- NCT06158269
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- 分期
- II期
- 开始
- 2022-04
- 登记号
- NCT05294055
年龄 18 岁 至 65 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州
- 正在招募ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- 分期
- I/II期
- 开始
- 2022-07
- 登记号
- NCT05632380
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募National Longitudinal Cohort of Hematological Diseases
- 分期
- 未注明
- 开始
- 2020-12
- 登记号
- NCT04645199
年龄未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- 分期
- 早期I期
- 开始
- 2026-01
- 登记号
- NCT07399444
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 4 家列出的医院为研究中心南昌、天津、徐州、武汉、郑州
- 即将招募A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- 分期
- 早期I期
- 开始
- 2026-04
- 登记号
- NCT07539233
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- 分期
- I/II期
- 开始
- 2026-08
- 登记号
- NCT07687004
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2026-07
- 登记号
- NCT07726160
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- 分期
- II期
- 开始
- 2026-09
- 登记号
- NCT07811986
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- 分期
- II期
- 开始
- 2026-10
- 登记号
- NCT07830485
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- 分期
- II期
- 开始
- 2026-12
- 登记号
- NCT07903636
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- 分期
- I期
- 开始
- 2026-02
- 登记号
- NCT07409246
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心天津、杭州
- 正在招募A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-03
- 登记号
- NCT07452198
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07518186
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春
- 正在招募Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2026-03
- 登记号
- NCT07529782
年龄 未注明 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州
- 正在招募Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07555938
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛
- 正在招募A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-01
- 登记号
- NCT07579234
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- 分期
- I期
- 开始
- 2026-09
- 登记号
- NCT07620275
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国人民解放军总医院;另有 2 家列出的医院为研究中心北京、天津
- 正在招募GR1803 Injection in Patients With RRMM
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT06952075
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- 分期
- II期
- 开始
- 2025-09
- 登记号
- NCT07018050
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- 分期
- 不分期
- 开始
- 2025-09
- 登记号
- NCT07100067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉
- 正在招募A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- II期
- 开始
- 2025-07
- 登记号
- NCT07312188
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- 分期
- I/II期
- 开始
- 2024-02
- 登记号
- NCT06232096
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2024-05
- 登记号
- NCT06375044
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州
- 正在招募Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- 分期
- 未注明
- 开始
- 2024-12
- 登记号
- NCT07028970
年龄未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州
- 正在招募Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- 分期
- III期
- 开始
- 2022-09
- 登记号
- NCT05243797
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春
- 正在招募A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2022-11
- 登记号
- NCT05521802
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
- 正在招募A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- 分期
- III期
- 开始
- 2022-11
- 登记号
- NCT05623020
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春
- 正在招募A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- II期
- 开始
- 2021-02
- 登记号
- NCT04634552
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安
- 正在招募A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- 分期
- I/II期
- 开始
- 2021-09
- 登记号
- NCT04973605
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛
- 正在招募A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- 分期
- III期
- 开始
- 2021-10
- 登记号
- NCT05020236
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春
- 即将招募Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-12
- 登记号
- NCT07910903
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 即将招募Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
- 分期
- III期
- 开始
- 2025-09
- 登记号
- NCT07181239
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 即将招募A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2024-08
- 登记号
- NCT06500507
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文47
- Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma.
- Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
- Prodigiosin inhibits proliferation and induces apoptosis through influencing amino acid metabolism in multiple myeloma.
- Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma.
- Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma.
- Identification and transformation of novel targets for immunotherapy in multiple myeloma.
- Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.
- Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation.
- Raman spectroscopy of dried serum for the detection of rapid noninvasive multiple myeloma.
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
- T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.
- Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
- Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
- Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
- Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
- Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.
- Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
- CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.
- B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.
- DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.
- LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.
- Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
- Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
- Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.
- Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
- Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.
- Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
- Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.
- Immunotherapy for multiple myeloma: new chances and hope.
- Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
- CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression.
- Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
- Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
- Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma.
- Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment.
- Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
- The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
- The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.
- Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.
- Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
- Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.
- Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
- Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.
- Comparative analysis of three serum-free light-chain detection systems in the diagnosis of multiple myeloma.
- A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
- The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
- Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance.
中文论文(未计入)17
- [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].
- [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
- [Clinical analysis of 14 patients aged ≤ 50 years with high-risk multiple myeloma treated with allogeneic hematopoietic stem cell transplantation].
- [Establishment of Patient-Derived Xenograft (PDX) Zebrafish Model of Multiple Myeloma and Its Application in Drug Screening].
- [Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma].
- [Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma].
- [The Clinical Significance of Oligoclonal Bands in Patient with Multiple Myeloma].
- [Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma].
- [Diagnostic and prognostic value of serum miR-19a-3p in patients with multiple myeloma].
- [Establishment and comparison of three human multiple myeloma cell line transplantation models in mice].
- [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
- [Cdc37 Expression in Multiple Myeloma and Its Role in Cell Proliferation].
- [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].
- [Clinical Analysis of Patients with MGUS, Primary Light Chain Amyloidosis, Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis].
- [Immunoglobulin M multiple myeloma: a six-case report and literature review].
- [Progress in clonal evolution of multiple myeloma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)92
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
- CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
- Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
- A Study of CT0596 in Plasma Cell Leukemia
- MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
- BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
- Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- BCMA CAR-T for Dynamic High-risk Multiple Myeloma
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- National Longitudinal Cohort of Hematological Diseases
- A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
- YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
- Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
- A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
- A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
- BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
- CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma
- ctDNA Methylation Sequencing for Myeloma
- Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
- Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
- Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
- LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- GR1803 Injection in Patients With RRMM
- A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
- Study of 3D189 in Patients With Hematologic Malignancies
- BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- A Study of Daratumumab
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of TQB3820 in Patients With Hematological Malignancies
- A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
- Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 13 篇,占 5.8%。
天津有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 20
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- 分期
- II/III期
- 开始
- 2025-01
- 登记号
- NCT06764238
年龄 1 个月 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛
- 正在招募Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- 分期
- II/III期
- 开始
- 2025-03
- 登记号
- NCT06882057
年龄 1 岁 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛
- 正在招募CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- 分期
- I期
- 开始
- 2025-06
- 登记号
- NCT07106749
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT07152041
年龄 1 个月 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛
- 正在招募CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- 分期
- 不分期
- 开始
- 2024-02
- 登记号
- NCT06355739
年龄 3 岁 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- 分期
- II期
- 开始
- 2024-04
- 登记号
- NCT06387121
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- 分期
- 不分期
- 开始
- 2024-06
- 登记号
- NCT06481228
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- 分期
- 不分期
- 开始
- 2024-06
- 登记号
- NCT06481241
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- 分期
- II期
- 开始
- 2024-08
- 登记号
- NCT06608732
年龄 16 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- 分期
- I期
- 开始
- 2026-04
- 登记号
- NCT07539610
年龄 18 岁 至 69 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- 分期
- II期
- 开始
- 2026-10
- 登记号
- NCT07840976
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- 分期
- I期
- 开始
- 2025-11
- 登记号
- NCT07234045
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Phase I Study of FXS0683 in the Treatment of Blood Tumors
- 分期
- I期
- 开始
- 2026-06
- 登记号
- NCT07616089
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- 分期
- I/II期
- 开始
- 2025-02
- 登记号
- NCT06481735
年龄 16 岁 至 70 岁(登记的条件)
牵头:中国人民解放军总医院;另有 3 家列出的医院为研究中心北京、天津
- 正在招募A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- 分期
- 早期I期
- 开始
- 2025-09
- 登记号
- NCT07205315
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- 分期
- II期
- 开始
- 2024-01
- 登记号
- NCT06179524
年龄 未注明 至 25 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06450067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州
- 正在招募A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- 分期
- I/II期
- 开始
- 2023-02
- 登记号
- NCT05667506
年龄 3 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆
- 正在招募A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- 分期
- II期
- 开始
- 2022-01
- 登记号
- NCT05334823
年龄 3 岁 至 21 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、苏州、郑州、重庆、长沙
- 正在招募A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- 分期
- I/II期
- 开始
- 2022-11
- 登记号
- NCT05579132
年龄 2 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文13
- Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.
- Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.
- Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.
- Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.
- Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.
- Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.
- Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
- Functional diversification and dynamics of CAR-T cells in patients with B-ALL.
- Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report.
- Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
- A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
- Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
中文论文(未计入)4
- [How I manage relapsed/refractory B-cell acute lymphoblastic leukemia patients treated with CD19 CAR- T cells throughout whole-process management].
- [The safety and efficacy of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia in children].
- [Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia].
- [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
- CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
- CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
- CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
- Phase I Study of FXS0683 in the Treatment of Blood Tumors
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
- CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 48 篇,占 11.7%。
天津有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
这家医院参与的开放试验 10
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
- 分期
- 未注明
- 开始
- 2026-02
- 登记号
- NCT07461116
年龄未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- 分期
- I/II期
- 开始
- 2026-06
- 登记号
- NCT07714512
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Reproductive and Mental Health of Patients With Aplastic Anemia
- 分期
- 未注明
- 开始
- 2025-03
- 登记号
- NCT06936930
年龄 18 岁 至 40 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT07010237
年龄 65 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- 分期
- I/II期
- 开始
- 2025-12
- 登记号
- NCT07287228
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- 分期
- 未注明
- 开始
- 2025-10
- 登记号
- NCT07578675
年龄 18 岁 至 65 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- 分期
- II期
- 开始
- 2023-02
- 登记号
- NCT06254560
年龄 18 岁 至 70 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募National Longitudinal Cohort of Hematological Diseases
- 分期
- 未注明
- 开始
- 2020-12
- 登记号
- NCT04645199
年龄未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
- 分期
- II期
- 开始
- 2025-07
- 登记号
- NCT07078721
年龄 18 岁 至 50 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 即将招募Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- 分期
- I/II期
- 开始
- 2025-03
- 登记号
- NCT06791824
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文48
- Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.
- Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study.
- The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.
- Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.
- Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.
- Comparison of Hetrombopag and Eltrombopag Added to First-Line Immunosuppressive Therapy in Severe Aplastic Anemia.
- Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.
- Cost utility analysis of adult patients with severe aplastic anemia: a single-center study.
- Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia.
- A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses.
- Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.
- Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.
- Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.
- Encephalitozoon hellem infection after haploidentical allogeneic hematopoietic stem cell transplantation in children: a case report.
- Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation.
- Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.
- Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine.
- Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.
- Haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propensity score-matched analysis.
- Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.
- Long-term outcomes of aplastic anemia with cytogenetic abnormalities at diagnosis.
- Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.
- Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia.
- Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia.
- Interleukin-10 promoter variability is associated with the susceptibility, severity, and clinical outcomes of aplasitc anemia in Han-Chinese population.
- Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia.
- Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
- Application of serum Raman spectroscopy in rapid and early discrimination of aplastic anemia and myelodysplastic syndrome.
- Impaired immunosuppressive effect of bone marrow mesenchymal stem cell-derived exosomes on T cells in aplastic anemia.
- Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.
- First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.
- Leptin-mediated proinflammatory bone marrow environment in acquired aplastic anemia.
- The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study.
- Levamisole Suppresses CD4+ T-Cell Proliferation and Antigen-Presenting Cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways.
- Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors.
- Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.
- Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia.
- Short Stature in Patients with Diamond-Blackfan Anemia: A Cross-Sectional Study.
- Efficacy of anti-thymocyte globulin for platelet transfusion refractoriness in serious aplastic anemia patients.
- PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis.
- Red blood cell lifespan is reduced in severe aplastic anemia and improves with response to immunosuppressive treatment.
- Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia.
- Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine.
- Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia.
- Successful Treatment of a 19-Month-Old Boy with Hepatitis Associated Aplastic Anemia by Infusion of Umbilical Cord-Derived Mesenchymal Stromal Cells: A Case Report.
- Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.
- Platelet/Lymphocyte ratio independently predicts the outcome of severe aplastic anemia patients treated with antithymocyte globulin.
- Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis.
中文论文(未计入)24
- [Advancements in CRISPR-Cas9 for Fanconi anemia].
- [Melatonin-Mediated Inhibitory Effect on Hyperimmune Status of Acquired Aplastic Anemia].
- [Clinical characteristics of aplastic anemia patients with abnormal autoantibodies and the impact of autoantibodies on immunosuppressive therapy response].
- [Evaluation of the clinical manifestations of COVID-19 in patients with aplastic anemia undergoing immunosuppressive therapy: a prospective cohort study (NICHE)].
- [Efficacy and safety of allogeneic hematopoietic stem cell transplantation in the treatment of 28 patients with hepatitis-related aplastic anemia].
- [Metagenomic next-generation sequencing of plasma for the identification of bloodstream infectious pathogens in severe aplastic anemia].
- [The effect of on-demand glucocorticoid strategy on the occurrence and outcome of p-ALG-associated serum sickness in aplastic anemia].
- [Clinical analysis of 76 patients with severe aplastic anemia treated with haploid hematopoietic stem cell transplantation].
- [T-large granular lymphocytic leukemia presenting as aplastic anemia: a report of five cases and literature review].
- [Prevalence and risk factors of obesity in children with Diamond-Blackfan anemia].
- Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia.
- [Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients].
- [Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia].
- [Kinetics of immune activated T cells in aplastic anemia mouse model].
- [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia].
- [Reassessing the six months prognosis of patients with severe or very severe aplastic anemia without hematological responses at three months after immunosuppressive therapy].
- [Bone marrow failure with body deformities].
- Research advances on haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia in children.
- [Clinical Characteristics and Prognosis Analysis of Pediatric Severe Aplastic Anemia].
- [Optimization of Mouse Model of Aplastic Anemia Induced by Pan T Lymphocytes Combined with Irradiation].
- [Relationship between Changes of Lymphocyte Subsets and Early Hematologic Response in Immunosuppressive Therapy of Severe Aplastic Anemia Patients].
- [Advances in bone marrow failure related ribosomopathies].
- [Syngeneic hematopoietic stem cell transplantation for aplastic anemia].
- [A real-world study of 176 cases with aplastic anemia treated in outpatient].
它在 ClinicalTrials.gov 上的全部试验(任何状态)35
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
- Reproductive and Mental Health of Patients With Aplastic Anemia
- Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
- Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
- Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- National Longitudinal Cohort of Hematological Diseases
- CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
- Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
- Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
- Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
- Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
- Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
- Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly
- The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA
- A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency
- Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia
- Avatrombopag Combined With IST as First-line Treatment for SAA
- Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA
- Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
- A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Combined With Standard Immunosuppressants in the Treatment of Children With Severe Aplastic Anemia
- A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
- Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived)
- Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
- Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
- Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
- Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia
- Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
- Extension Study of Hetrombopag in Severe Aplastic Anemia
- A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
天津有 1 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募β-Thalassemia Treatment With KL003 Cell Injection
- 分期
- I/II期
- 开始
- 2024-04
- 登记号
- NCT06280378
年龄 3 岁 至 35 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、天津
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
- Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
- Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
- Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
- Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia
- Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
- β-Thalassemia Treatment With KL003 Cell Injection
- A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 25 篇,占 9.2%。
天津有 1 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
- 分期
- 早期I期
- 开始
- 2024-01
- 登记号
- NCT06238908
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- 分期
- IV期
- 开始
- 2023-11
- 登记号
- NCT05888870
年龄 14 岁 至 65 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募A Study of FVIII Gene Therapy for Hemophilia A
- 分期
- 早期I期
- 开始
- 2022-07
- 登记号
- NCT05454774
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募Gene Therapy for Chinese Hemophilia A
- 分期
- 不分期
- 开始
- 2021-03
- 登记号
- NCT04728841
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募National Longitudinal Cohort of Hematological Diseases
- 分期
- 未注明
- 开始
- 2020-12
- 登记号
- NCT04645199
年龄未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所)天津
- 正在招募A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07416604
年龄 12 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、广州、福州
- 正在招募Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
- 分期
- III期
- 开始
- 2026-03
- 登记号
- NCT07545395
年龄 12 岁 至 65 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津
- 正在招募To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT06833983
年龄 18 岁 至 65 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙
- 正在招募Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- 分期
- II/III期
- 开始
- 2024-01
- 登记号
- NCT06111638
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙
- 正在招募A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- 分期
- III期
- 开始
- 2022-12
- 登记号
- NCT05611801
年龄 1 岁 至 17 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉
- 正在招募Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- 分期
- III期
- 开始
- 2021-11
- 登记号
- NCT05145127
年龄 1 岁 至 74 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、广州、武汉、贵阳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文25
- Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.
- The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.
- Nationwide Survey of Laboratory Practices for Factor VIII Inhibitor Detection in China.
- The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.
- Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A.
- Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.
- Decoding the complexity of on-target integration: characterizing DNA insertions at the CRISPR-Cas9 targeted locus using nanopore sequencing.
- Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.
- Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.
- Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.
- Women and girls with haemophilia: A retrospective cohort study in China.
- Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.
- Anti-CD38 antibody for refractory acquired hemophilia A.
- Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors.
- Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
- Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
- Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population.
- Haemophilia gene therapy-Update on new country initiatives.
- Demographics, clinical profile and treatment landscape of patients with haemophilia B in China.
- Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A.
- Total Knee Arthroplasty after Gene Therapy for Hemophilia B.
- Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices.
- Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up.
- Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
- An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies.
中文论文(未计入)5
- [How I treat acquired clotting factor deficiency].
- [Clinical efficacy and safety of Octocog alfa in Chinese patients with hemophilia A: One-year follow-up results from the Antihemophilic Factor Hemophilia A Outcome Database (AHEAD) study].
- [Keeping up with the trends and improving the hierarchical system for the diagnosis and treatment of hemophilia in China].
- [Recent advances in the replacement therapy for Hemophilia].
- [Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B].
早期论文(2016–2020 年)19
- Growing success and ambitions of the Chinese edition of Haemophilia.
- Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.
- Haemophilia care in China: Achievements in the past decade.
- Real-world analysis of haemophilia patients in China: A single centre's experience.
- Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China.
- Outcome of CARE: a 6-year national registry of acquired haemophilia A in China.
- Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.
- Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
- [How I treat hemophilia with inhibitors].
- [HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy].
- [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].
- [Clinical application and optimization of HEAD-US quantitative ultrasound assessment scale for hemophilic arthropathy].
- Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
- [Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab].
- [Advances in Hemophilia A inhibitors].
- [Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders].
- [Retrospectively analysis of the difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients].
- Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.
- [Study on risk factors and follow-up of 26 hemophilia A children with inhibitors].
它在 ClinicalTrials.gov 上的全部试验(任何状态)47
- Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
- ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
- A Study of FVIII Gene Therapy for Hemophilia A
- Gene Therapy for Chinese Hemophilia A
- National Longitudinal Cohort of Hematological Diseases
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
- The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
- Data Registry in Chinese Hemophilia A and B Patients
- Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
- To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
- Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
- A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
天津有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
天津有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
这些数字背后的记录
牵头的论文3
- Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.
- Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.
- Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
天津有 5 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
天津有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
戈谢病
Gaucher disease2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
天津有 3 家医院列在戈谢病下全国有 41 家医院列在戈谢病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06818838
年龄 18 岁 至 60 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心天津、太原、广州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
早期论文(2016–2020 年)1
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
天津有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
联系这家医院
出示给工作人员或司机的院名卡
中国医学科学院血液病医院(血液学研究所)
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
天津
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Yunnan Blood Disease Hospital; Insitute of Hematology & Blood Disarses Hospital; Blood Disease Hospital; Blood Diseases Hospital; Hematology and Blood Diseases Hospital; Institute of Hematology & Blood Diseases Hospital; Institute of Hematology and Blood Diseases Hospital; 中国医学科学院血液病医院